I klinisk praksis vil dette betyde, at moxifloxacin skal bruges i kombination med et godkendt stof, der er aktivt imod fluoroquinolon- resistente N. gonorrhoeae- stammer (f. eks. cephalosporin) i forbindelse med empirisk behandling af PID, medmindre moxifloxacin- resistente N. gonorrhoeae- stammer kan udelukkes.
In clinical practice, this would mean that moxifloxacin should be used in combination with an approved agent active against fluoroquinolone resistant N. gonorrhoeae (e. g. a cephalosporin) for empirical treatment of PID unless moxifloxacin- resistant N. gonorrhoeae can be excluded.